SLC22A1: Unlocking The Potential of Drug Transport and Disease Regulation

Target Name: SLC22A1

NCBI ID: G6580

SLC22A1

SLC22A1: Unlocking The Potential of Drug Transport and Disease Regulation

SLC22A1 (OCT1) is a gene that encodes a protein known as solute carrier family 22 member 1 (SLC22A1). The SLC22A1 protein is a type of transport protein that is involved in the transport of various substances, including drugs, mutations, and diseases, within the body. It is a protein that is expressed in many different tissues and cells throughout the body, including the brain, heart, liver, kidney, and intestine.

One of the unique features of SLC22A1 is its ability to transport drugs across cell membranes. This is an important function of the protein, as drugs are often used to treat various diseases and conditions. For example, SLC22A1 has been used to transport drugs such as insulin, growth hormone, and morphine, among others, across cell membranes to treat conditions such as diabetes, growth disorders, and pain.

In addition to its role in drug transport, SLC22A1 has also been shown to play a key role in the regulation of various physiological processes in the body. For example, studies have shown that SLC22A1 is involved in the uptake and release of nutrients, such as oxygen and carbon dioxide, from the bloodstream to the body's cells. It is also involved in the regulation of water and electrolyte balance within the body.

SLC22A1 has also been shown to be involved in the development and progression of certain diseases. For example, studies have shown that SLC22A1 is involved in the development of cancer, particularly ovarian cancer. It is also involved in the regulation of cell division and has been shown to play a key role in the development of certain types of neurodegenerative diseases.

Despite its many important functions, SLC22A1 is not yet a well-studied protein. There are only a few studies that have investigated its role in various physiological processes and its involvement in the development of certain diseases. Therefore, there is a need for further research to fully understand the protein's role in the body and its potential as a drug target or biomarker.

In conclusion, SLC22A1 is a protein that is involved in a variety of important functions in the body. Its ability to transport drugs across cell membranes makes it an attractive target for drug development, and its role in the regulation of various physiological processes and its involvement in the development of certain diseases make it a promising biomarker for diagnostic and therapeutic applications. Further research is needed to fully understand the protein's role in the body and its potential as a drug target or biomarker.

Protein Name: Solute Carrier Family 22 Member 1

Functions: Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics (PubMed:9260930, PubMed:9187257, PubMed:11388889, PubMed:9655880, PubMed:11408531, PubMed:15389554, PubMed:16263091, PubMed:16272756, PubMed:16581093, PubMed:19536068, PubMed:21128598, PubMed:23680637, PubMed:24961373, PubMed:34040533, PubMed:12439218, PubMed:12719534). Functions as a pH- and Na(+)-independent, bidirectional transporter (By similarity). Cation cellular uptake or release is driven by the electrochemical potential (i.e. membrane potential and concentration gradient) and substrate selectivity (By similarity). Hydrophobicity is a major requirement for recognition in polyvalent substrates and inhibitors (By similarity). Primarily expressed at the basolateral membrane of hepatocytes and proximal tubules and involved in the uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow (By similarity). Most likely functions as an uptake carrier in enterocytes contributing to the intestinal elimination of organic cations from the systemic circulation (PubMed:16263091). Transports endogenous monoamines such as N-1-methylnicotinamide (NMN), guanidine, histamine, neurotransmitters dopamine, serotonin and adrenaline (PubMed:9260930, PubMed:24961373, PubMed:35469921, PubMed:12439218). Also transports natural polyamines such as spermidine, agmatine and putrescine at low affinity, but relatively high turnover (PubMed:21128598). Involved in the hepatic uptake of vitamin B1/thiamine, hence regulating hepatic lipid and energy metabolism (PubMed:24961373). Mediates the bidirectional transport of acetylcholine (ACh) at the apical membrane of ciliated cell in airway epithelium, thereby playing a role in luminal release of ACh from bronchial epithelium (PubMed:15817714). Transports dopaminergic neuromodulators cyclo(his-pro) and salsolinol with lower efficency (PubMed:17460754). Also capable of transporting non-amine endogenous compounds such as prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) (PubMed:11907186). May contribute to the transport of cationic compounds in testes across the blood-testis-barrier (Probable). Also involved in the uptake of xenobiotics tributylmethylammonium (TBuMA), quinidine, N-methyl-quinine (NMQ), N-methyl-quinidine (NMQD) N-(4,4-azo-n-pentyl)-quinuclidine (APQ), azidoprocainamide methoiodide (AMP), N-(4,4-azo-n-pentyl)-21-deoxyajmalinium (APDA) and 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP) (PubMed:9260930, PubMed:11408531, PubMed:15389554, PubMed:35469921)

The "SLC22A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets